share_log

金斯瑞生物科技:董事會會議日期

GENSCRIPT BIO: DATE OF BOARD MEETING

HKEX ·  Jul 30 04:32

Summary by Moomoo AI

金斯瑞生物科技股份有限公司宣布,將於2024年8月9日(星期五)召開董事會會議,屆時將考慮及批准截至2024年6月30日止六個月的中期業績及其發佈。會議同時將考慮是否派發中期股息。該公司由孟建革擔任主席及執行董事,並有章方良博士、王燁女士、朱力博士等人擔任執行董事,王魯泉博士為非執行董事,戴祖勉先生、潘九安先生、張耀樑先生及施晨陽博士為獨立非執行董事。會議的具體議程包括審核及批准中期業績報告和決定中期股息分派事宜。
金斯瑞生物科技股份有限公司宣布,將於2024年8月9日(星期五)召開董事會會議,屆時將考慮及批准截至2024年6月30日止六個月的中期業績及其發佈。會議同時將考慮是否派發中期股息。該公司由孟建革擔任主席及執行董事,並有章方良博士、王燁女士、朱力博士等人擔任執行董事,王魯泉博士為非執行董事,戴祖勉先生、潘九安先生、張耀樑先生及施晨陽博士為獨立非執行董事。會議的具體議程包括審核及批准中期業績報告和決定中期股息分派事宜。
Genscript Bio announced that the Board of Directors meeting will be held on Friday, August 9, 2024, where they will consider and approve the mid-term performance report until June 30, 2024, as well as its release. The meeting will also consider whether to distribute mid-term dividends. The company is chaired and held by Executive Director Meng Jiangge, with Executive Directors Dr. Zhang Fangliang, Ms. Wang Ye, and Dr. Zhu Li and Non-Executive Director Dr. Wang Luquan. Mr. Dai Zumian, Mr. Pan Jiu'an, Mr. Zhang Yaoliang, and Dr. Shi Chenyang serve as independent-non-executive directors. The specific agenda of the meeting includes reviewing and approving the mid-term performance report and deciding on the distribution of mid-term dividends.
Genscript Bio announced that the Board of Directors meeting will be held on Friday, August 9, 2024, where they will consider and approve the mid-term performance report until June 30, 2024, as well as its release. The meeting will also consider whether to distribute mid-term dividends. The company is chaired and held by Executive Director Meng Jiangge, with Executive Directors Dr. Zhang Fangliang, Ms. Wang Ye, and Dr. Zhu Li and Non-Executive Director Dr. Wang Luquan. Mr. Dai Zumian, Mr. Pan Jiu'an, Mr. Zhang Yaoliang, and Dr. Shi Chenyang serve as independent-non-executive directors. The specific agenda of the meeting includes reviewing and approving the mid-term performance report and deciding on the distribution of mid-term dividends.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more